Then, we analyzed the effects of MCT1 and MCT4 inhibition in AML cell lines and primary leukemic blasts, by using AR-C, a potent inhibitor of MCT1, with an analogue AZD3965 currently tested in clinical trials for several types of cancer (42), and SYRO, an antihypertensive agent that was found to potentiate the anticancer effects of the antidiabetic agent metformin and described as a dual inhibitor of MCT1 and 4 but with a major affinity for MCT4 (8). Here, SLC16A1 is linked to cancer.